Meeting Highlights
Miami, March 27, 2009
Maui, January 14-17, 2009
San Francisco, October 24-29, 2008
Paris, June 11-14, 2008
Chicago, April 10, 2008
San Francisco, March 5-9, 2008
BioPharm Business News
Wednesday, December 02, 2009
OxyPharma's New RA Drug Shows Positive Phase II Results
Rabeximod, an orally-administered DMARD, showed promise as a new RA treatment during a 16-week study...
Thursday, November 19, 2009
French Government Buys Into Naproxinod
NicOx has submitted an NDA for naproxinod for osteoarthritis, and is raising $149 million for the launch...
Wednesday, November 18, 2009
FDA Wants Pain Pump Label Warnings
Chondrolysis follows continuous intra-articular local anesthetic infusion, FDA says...
Thursday, November 12, 2009
Bristol Set to Challenge Roche for RA IL-6 Blockers
Bristol-Myers Squibb has licensed RA indications for Alder's ALD518 anti-IL-6 monoclonal...
Wednesday, October 28, 2009
Third RA Patient Has PML After Rituximab
The FDA's MedWatch warning system reports that a third rheumatoid arthritis (RA) patient treated with Genentech's Rituxan (rituximab) has developed PML, this time without prior anti-TNF exposure...
Monday, October 19, 2009
Denosumab Approval Faces Delay
FDA-watchers predict that the agency will miss the October 19th target set for denosumab approval by as much as 3 months...